ArticleCureus2025
Defying the Odds: Small Cell Lung Cancer with Essential Thrombocythemia and Secondary Cancers.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small cell lung cancer (SCLC) is an aggressive malignancy with historically poor survival outcomes, especially in patients with significant comorbidities. This report presents a rare case of a 65-year-old woman with limited-stage SCLC and JAK2-positive essential thrombocythemia (ET), who subsequently developed multiple malignancies including papillary thyroid carcinoma, right-sided colon adenocarcinoma, and basal cell carcinoma. Despite serious complications such as subdural hematoma and intra-abdominal bleeding, the patient remains clinically stable over a decade after her initial diagnosis. Genetic testing revealed no hereditary cancer syndromes, suggesting a potential role of chronic inflammation and prior therapies in her cancer trajectory. This case underscores the importance of early aggressive therapy, vigilant long-term follow-up, and multidisciplinary coordination in managing complex oncologic and hematologic conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.